Related Experiment Video
Updated: Feb 17, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Erdheim-Chester Disease with No Skeletal Bone Involvement and Massive Weight Loss
Hind Salama1, Suleiman Kojan2,3, Shaima Abdulrahman4
1Division of Hematology and HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Insights
Erdheim-Chester disease (ECD) is a rare histiocytosis. This case highlights a unique presentation in a younger patient with cerebellar atrophy and significant weight loss, responding well to vemurafenib.
Area of Science:
- Rare diseases
- Histiocytosis
- Genetics
Background:
- Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis.
- Characterized by multiorgan histiocytic infiltration, typically presenting in adults 40-70 years old.
- Bone disease with long bone sclerosis is the most common symptom (96% of cases), and BRAF V600E mutation is found in 60%.
Observation:
- A unique ECD case in a younger patient with no bone pain or skeletal involvement.
- Presented with significant unintentional weight loss (50% body mass) and progressive cerebellar manifestations.
- Radiological evidence showed cerebellar atrophy, contrasting with typical ECD cerebellar infiltration.
Findings:
- The patient exhibited cardiac, retroperitoneal, and perinephric involvement.
- Tissue biopsy confirmed ECD morphology and immunohistochemistry, with BRAF V600E mutation detected.
- Despite retaining sexual drive and fertility, the patient's disease progressed on pegylated interferon alpha.
Implications:
- Vemurafenib demonstrated an excellent response within 6 weeks, suggesting its potential efficacy in atypical ECD cases.
- This case expands the understanding of ECD's diverse clinical spectrum and treatment responses.
- Highlights the importance of considering atypical presentations and targeted therapies like BRAF inhibitors in ECD management.
Abstract:
Erdheim-Chester disease (ECD) is a rare type of non-Langerhans cell histiocytosis, with only 550 cases reported worldwide. ECD is characterized by diffuse histiocytic infiltration of multiorgans. The age of presentation of this disease is typically between 40 and 70 years. Bone disease is the most common symptom, as unique radiological findings of long bone sclerosis occur in 96% of cases. Furthermore, BRAF V600E mutation is detected in 60% of ECD cases. In this manuscript, we are describing a unique case of ECD; the patient is younger than most reported cases and has no bone pain or any skeletal involvement. This patient has unintentionally lost about 50% of his body mass and is suffering from progressive cerebellar manifestations with radiological evidence of cerebellar atrophy, in contrast to the usual ECD manifestation of cerebellar infiltration. In addition, the patient has cardiac, retroperitoneal, and perinephric involvement, but he retains his sexual drive and fertility. A tissue biopsy from the retroperitoneal mass displayed typical morphological and immunohistochemical features of ECD, and BRAF V600E mutation was detected. He was treated with pegylated interferon alpha, but his disease progressed and the treatment was changed to vemurafenib to which he had an excellent response at 6 weeks.
Related Concept Videos
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Endocarditis II: Clinical Features of Infective Endocarditis
Chronic Kidney Disease II: Clinical Manifestations
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Anorexia Nervosa
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...